Healthcare Industry News: CT colonography
News Release - June 13, 2007
Viatronix Inc. Receives CE Mark and Announces the Release of Their V3D-Colon Integrated with Medicsight ColonCAD.STONY BROOK, N.Y., June 13 (HSMN NewsFeed) -- Stony Brook based Viatronix Incorporated (www.viatronix.com), a leading innovator and developer of diagnostic 3D imaging software, and Medicsight PLC headquartered in London (www.medicsight.com), a leading developer of computer-aided detection (CAD) technologies, announced today the joint European commercial release of their integrated "virtual colonoscopy" products with CAD. Medicsight PLC will be presenting the integrated solution at the annual congress of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), which is being held in Lisbon, Portugal June 12-15, 2007.
The Viatronix V3D-Colon, integrated with Medicsight's CAD (Computer Aided Detection) system for performing virtual colonoscopy, has received the CE Mark for commercial sales in Europe. The integrated Viatronix V3D-Colon with Medicsight CAD aids physicians in the early detection and identification of polyps and has been tested at over twenty five sites all across Europe.
"We are pleased to be able to offer enhanced solutions to our customers in Europe. The integrated products provide additional tools, to improve the speed and efficiency of radiologists' workflow," said Zaffar Hayat, President of Viatronix.
"We are really excited about bringing the combined innovative and leading product to market and provide benefits for radiologists," says David Sumner, CEO of Medicsight PLC. "We are confident that the integrated solution will create an ideal workflow and optimize reading times for end user productivity, thereby giving Viatronix and Medicsight the opportunity to capitalize on the ever increasing customer demand for virtual colonoscopy with CAD."
The Viatronix V3D-Colon for "virtual colonoscopy" allows physicians to interactively view the colon as reconstructed from a CT (Computed Tomography) scan, providing visualization of the entire colon where polyps or other lesions may be located. Viatronix's V3D-Colon is the only system on the market that is backed by a landmark multi-center clinical trial showing 93.9% sensitivity and 92.2% specificity for adenomatous polyps sized 8mm and larger.
Medicsight ColonCAD API is an image-analysis software tool designed to be used with CT colonography (virtual colonoscopy) scans to assist radiologists in detecting and measuring potential colorectal polyps. Medicsight's ColonCAD products are seamlessly integrated within the advanced 3D visualisation and PACS platforms of industry-leading imaging equipment partners.
Developed using one of the world's largest and most population-diverse CT scan databases, Medicsight CAD products aim to assist radiologists in detecting colonic lesions, whilst providing valuable information to allow the radiologist to assess patient images more effectively. These products are designed to improve radiologists' workflow and productivity.
Viatronix is a leading innovator and developer of 2D/3D medical imaging and diagnostic software. Our software enables physicians to interactively view vital organs and anatomical structures within the human body from data acquired by standard medical imaging equipment in minimally or non-invasive methods. The 2D digital data acquired from imaging devices is automatically post processed using the company's proprietary software techniques and provides 3D diagnostic quality images for the physician.
The company's first product, V3D-Colon for "virtual colonoscopy" allows physicians to interactively view the colon reconstructed from a CT scan, providing visualization of the entire colon wall which includes polyps and other lesions. The company's V3D-Explorer offers a robust and user-friendly workstation platform that views and reconstructs data in 2D/3D for virtually any organ in the body. V3D-Calcium Scoring aids physicians in determining the amount of calcified plaque accumulation in the coronary arteries. V3D- Vascular is breakthrough software that permits rapid segmentation and visualization of complex arterial structures using 3D volume rendering, maximum intensity projection and simulated x-ray views. Viatronix, through application of the V3D technology, is developing additional innovative products that will be useful in early detection of other diseases, treatment planning, intervention and follow up evaluation. Viatronix, Inc. is located in Stony Brook, NY. For further information, call toll free 1-866-887-4636 or log on to: www.viatronix.com
About Medicsight PLC
Medicsight PLC is a leading developer of computer-aided detection (CAD) technologies and image analysis software. Medicsight PLC's software solutions help clinicians identify, measure and analyse suspicious pathology such as colorectal polyps and lung lesions on CT scans. The patent protected CAD technology developed by Medicsight PLC is validated against one of the world's largest and most population diverse databases of verified CT scan data. The company's products include ColonCAD(TM) and ColonCAR(TM), and LungCAD(TM) and LungCAR(TM). These products seamlessly integrate with the advanced 3D visualisation platforms of industry leading partners. Medicsight is committed to the ongoing development of innovative global solutions for improving clinicians' workflow to support the detection, interpretation and diagnosis of disease at the earliest possible stage. Headquartered in London, Medicsight PLC employs more than 50 people and also has offices in the United States and Japan. Medicsight PLC product and company information can be found on www.medicsight.com.
All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.